<DOC>
	<DOCNO>NCT02606279</DOCNO>
	<brief_summary>This study design evaluate specific factor mitochondria may precipitate premature age physical weakness HIV patient . Angiotensin receptor 1 2 ( AT1R AT2R ) find virtually every cell type . This study evaluate relationship among receptor immune skeletal muscle cell change HIV , change might trigger mitochondrial dysfunction , decline muscle strength , cellular decline people live HIV .</brief_summary>
	<brief_title>Angiotensin Receptors Age Related Mitochondrial Decline HIV Patients</brief_title>
	<detailed_description>HIV related premature cellular age decline mitochondrial function closely link . Dysfunctional mitochondrion generate high level reactive oxygen specie ( ROS ) provide less ATP supply cellular energy . Impaired turnover damage mitochondrion lead gradual progressive decline energy metabolism , increase muscle fibrosis clinically apparent weakness . The Renin Angiotensin System ( RAS ) central hormonal system contribute mitochondrial dysfunction impact lifespan function across multiple organ system . Deletion angiotensin type 1 receptor ( AT1R ) result 25-30 % extension lifespan mouse model , partly increase mitochondrial number . Blocking AT1R reduces number age-related morbidity mouse , human study . A plethora data implicates RAS modulation mark effect fitness , frailty beneficial response exercise old adult . Despite , virtually data examine RAS biology HIV+ vs. age-matched HIVsubjects , data RAS relation key HIV-specific variable ( duration HIV , treatment history , immune marker ) , data examine effect block AT1R physical function HIV infect subject . In study , examine RAS contribution premature mitochondrial failure HIV patient . We begin fill void enrol 40 HIV+ subject randomize , double-blinded , placebo control pilot study treatment AT1R blocker determine feasibility large trial , estimate effect size , assess correlation angiotensin receptor ( AR ) expression peripheral blood cell muscle cell , association AR expression physical function measure immunity .</detailed_description>
	<mesh_term>Sarcopenia</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>able provide inform consent able attend extend ( ~4 hour ) Clinical Research Visit document HIV seropositivity stable antiretroviral therapy ( ART ) regimen least 12 month HIV plasma viral load &lt; 50 copies/ml least 6 month Systolic blood pressure &gt; 110 creatinine &gt; 1.5 ULN ( creatinine clearance &lt; 60 ml/min ) antihypertensive therapy ACEI AT1Rblockers inability perform functional measure ( e.g . nonambulatory without assistance , require prosthesis ) recent ( within 30 day ) acute illness require medical therapy hospitalization immunosuppressive agent ( e.g . &gt; 20 mg/d x 2 week prednisone equivalent , chemotherapy ) last 6 month cancer require treatment w/in 3 yr ( except nonmelanoma skin cancer ) blood thin medication Coumadin Plavix bleed disorder hemophilia could cause complication muscle biopsy pregnancy ( provide urine test female child bear potential ) regular use nonsteroidal antiinflammatory drug immune modulate agent .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>